Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 09:43 ET | Source: Applied Pharmaceutical Innovation (API)

Applied Pharmaceutical Innovation Appoints Dr. Launa Aspeslet as Chief Translational Officer to Accelerate Life Sciences Commercialization in Canada

Applied Pharmaceutical Innovation (API) appoints Dr. Launa Aspeslet as Chief Translational Officer to drive life sciences commercialization in Canada.
April 22, 2025 20:34 ET | Source: Recursion Pharmaceuticals

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data...
April 08, 2025 16:30 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
April 08, 2025 11:44 ET | Source: Research and Markets

LAG-3 Targeting Therapy Market & Clinical Trials Insight Report 2030: Insight on 35+ LAG-3 Targeted Therapies In Clinical Trials

Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report" report has been added to ...
April 08, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first...
April 02, 2025 08:37 ET | Source: Research and Markets

STAT3 Inhibitors Market Analysis & Clinical Trials Report 2025-2028: Innovation in Drug delivery and Formulation Techniques - Opportunities May Expand Beyond Oncology

Dublin, April 02, 2025 (GLOBE NEWSWIRE) -- The "STAT3 Inhibitors Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The market for...
March 25, 2025 09:56 ET | Source: Research and Markets

Personalized Cancer Vaccine Market & Clinical Trials Outlook 2025: BioNTech, Moderna and myNEO Therapeutics Lead Race in Personalized Cancer Vaccines

Dublin, March 25, 2025 (GLOBE NEWSWIRE) -- The "Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering. ...
March 24, 2025 06:59 ET | Source: Pasithea

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics (KTTA) will present PAS-004 Phase 1 data at the 2025 CAGLA NeauxCancer Conference on March 28 in New Orleans.
March 20, 2025 10:24 ET | Source: Research and Markets

Next-Gen Immunotherapy: Trispecific Antibodies Show 260x Potency Over Traditional Treatments

Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Trispecific Antibodies Clinical Trials, Fast Track Status, Technology Platforms & Market Opportunity Outlook 2025" report has been added to ...
March 20, 2025 09:00 ET | Source: Longeveron

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.

Next Page keyboard_arrow_right